Publication | Open Access
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
260
Citations
26
References
2019
Year
| Year | Citations | |
|---|---|---|
Page 1
Page 1